Literature DB >> 2543551

Mevalonate kinase in lysates of cultured human fibroblasts and lymphoblasts: kinetic properties, assay conditions, carrier detection and measurement of residual activity in a patient with mevalonic aciduria.

K M Gibson1, J L Lohr, R L Broock, G Hoffmann, W L Nyhan, L Sweetman, I K Brandt, R S Wappner, P I Bader.   

Abstract

An assay has been developed for the measurement of mevalonate kinase activity in extracts of cultured human fibroblasts and lymphoblasts. Individual elements of the assay were investigated in order to achieve optimum conditions. Apparent Michaelis constants (KMapp) for the substrates mevalonic acid and adenosine-5'-triphosphate were 22 +/- 10 mumol/l and 0.42-0.53 mmol/l, respectively, in lysates of control fibroblast lines. The same values in lysates of a control lymphoblast line were 17 mumol/l and 0.23 mmol/l, respectively. Mevalonate kinase activity in extracts of cultured fibroblasts derived from 6 control individuals was 3.24 +/- (SD) 0.91 nmol/min/mg protein. The activity in extracts of fibroblasts derived from a patient with mevalonic aciduria was 0.15 +/- 0.10 nmol/min/mg protein, approximately 5% of the control mean. The parents and brother of the patient displayed mevalonate kinase activities in fibroblast extracts approximating 38-42% of the control mean. Substantially higher mevalonate kinase activity was documented in extracts of cultured lymphoblasts. When assayed on various occasions, the mean activity of mevalonate kinase in extracts of lymphoblasts derived from the parents, brother and maternal grandmother of the patient ranged from 27 to 32% of the mean activity of 9.8 +/- (SD) 3.4 nmol/min/mg protein measured in a parallel control lymphoblast line, while the mean activity in a maternal and paternal uncle approximated 65-89% of the same control mean. The mean activity in extracts of lymphoblasts derived from the patient approximated 2% of the control mean. The data suggest that the parents, brother and maternal grandmother are carriers of the defective gene responsible for mevalonate kinase deficiency, consistent with an autosomal recessive mode of inheritance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543551     DOI: 10.1159/000469050

Source DB:  PubMed          Journal:  Enzyme        ISSN: 0013-9432


  6 in total

1.  Mevalonate kinase deficiency in a dizygotic twin with mild mevalonic aciduria.

Authors:  K M Gibson; G F Hoffmann; L Sweetman; B Buckingham
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

2.  Segregation of the N301T mutation in the family of the index patient with mevalonate kinase deficiency.

Authors:  B Goebel-Schreiner; R Schreiner; G F Hoffmann; K M Gibson
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

3.  Identification of a mutation cluster in mevalonate kinase deficiency, including a new mutation in a patient of Mennonite ancestry.

Authors:  D D Hinson; R M Ross; S Krisans; J L Shaw; V Kozich; M O Rolland; P Divry; J Mancini; G F Hoffmann; K M Gibson
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

4.  Mevalonate kinase assay using DEAE-cellulose column chromatography for first-trimester prenatal diagnosis and complementation analysis in mevalonic aciduria.

Authors:  G F Hoffmann; S U Brendel; S R Scharfschwerdt; Y S Shin; I M Speidel; K M Gibson
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

Review 5.  Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome.

Authors:  Dorothea Haas; Georg F Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2006-04-26       Impact factor: 4.123

6.  Increased core body temperature exacerbates defective protein prenylation in mouse models of mevalonate kinase deficiency.

Authors:  Marcia A Munoz; Oliver P Skinner; Etienne Masle-Farquhar; Julie Jurczyluk; Ya Xiao; Emma K Fletcher; Esther Kristianto; Mark P Hodson; Seán I O'Donoghue; Sandeep Kaur; Robert Brink; David G Zahra; Elissa K Deenick; Kristen A Perry; Avril Ab Robertson; Sam Mehr; Pravin Hissaria; Catharina M Mulders-Manders; Anna Simon; Michael J Rogers
Journal:  J Clin Invest       Date:  2022-10-03       Impact factor: 19.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.